Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2007; 13(2): 224-227
Published online Jan 14, 2007. doi: 10.3748/wjg.v13.i2.224
Published online Jan 14, 2007. doi: 10.3748/wjg.v13.i2.224
Figure 1 Randomized phase III trial comparing gemcitabine (Gem) vs gemcitabine plus cisplatin (Cis): Subgroups KPS 70%-80% and KPS 90%-100%; Progression-free survival (PFS) by treatment arm (HR = hazard ratio).
Figure 2 Randomized phase III trial comparing gemcitabine (Gem) vs gemcitabine plus cisplatin (Cis): Subgroups KPS 70%-80% and KPS 90%-100%; Overall survival (OS) by treatment arm (HR = hazard ratio).
- Citation: Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13(2): 224-227
- URL: https://www.wjgnet.com/1007-9327/full/v13/i2/224.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i2.224